Literature DB >> 2934406

Formation of soluble immune complexes by complement in sera of patients with various hypocomplementemic states. Difference between inhibition of immune precipitation and solubilization.

J A Schifferli, G Steiger, G Hauptmann, P J Spaeth, A G Sjöholm.   

Abstract

To examine whether the ability of complement to form soluble immune complexes plays a role in preventing immune complex-mediated diseases, we analyzed the capacity of complement to inhibit immune precipitation (IIP) and to solubilize preformed immune aggregates (SOL) in 23 sera of patients with various hypocomplementemic states, and we correlated the results of these studies with the clinical syndromes found in the various patients. In sera with deficiency or depletion of early classical pathway components, IIP was profoundly altered, whereas SOL was delayed but in the normal range. In contrast, in sera with C3 depletion but intact classical pathway and in properdin-deficient serum, IIP was initially preserved, whereas SOL was abolished. Since the incidence of immune complex diseases in various hypocomplementemic states correlates with the severity of IIP defects, but not with reduced SOL, it is suggested that IIP is an essential biological function of complement that prevents the rapid formation of insoluble immune complexes in vivo.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2934406      PMCID: PMC424324          DOI: 10.1172/JCI112217

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  35 in total

1.  Deficiency of C7 with systemic lupus erythematosus: solubilization of immune complexes in complement-deficient sera.

Authors:  H J Zeitz; G W Miller; T F Lint; M A Ali; H Gewurz
Journal:  Arthritis Rheum       Date:  1981-01

2.  The subunit composition and sedimentation properties of human C1.

Authors:  R J Ziccardi; N R Cooper
Journal:  J Immunol       Date:  1977-06       Impact factor: 5.422

3.  Requirements for the solubilization of immune aggregates by complement. The role of the classical pathway.

Authors:  M Takahashi; S Takahashi; V Brade; V Nussenzweig
Journal:  J Clin Invest       Date:  1978-08       Impact factor: 14.808

4.  Purification and radiolabeling of human C1q.

Authors:  A J Tenner; P H Lesavre; N R Cooper
Journal:  J Immunol       Date:  1981-08       Impact factor: 5.422

5.  Complement-mediated inhibition of immune precipitation. II. Analysis by sucrose density gradient ultracentrifugation.

Authors:  J A Schifferli; D K Peters
Journal:  Clin Exp Immunol       Date:  1982-03       Impact factor: 4.330

6.  Complement-mediated solubilization in patients with systemic lupus erythematosus, nephritis or vasculitis.

Authors:  J A Schifferli; S M Morris; A Dash; D K Peters
Journal:  Clin Exp Immunol       Date:  1981-12       Impact factor: 4.330

7.  Inhibition of immune precipitation by complement.

Authors:  J A Schifferli; S R Bartolotti; D K Peters
Journal:  Clin Exp Immunol       Date:  1980-11       Impact factor: 4.330

8.  Large scale isolation of functionally active components of the human complement system.

Authors:  C H Hammer; G H Wirtz; L Renfer; H D Gresham; B F Tack
Journal:  J Biol Chem       Date:  1981-04-25       Impact factor: 5.157

9.  Decreased capacity to solubilize immune complexes in sera from patients with systemic lupus erythematosus.

Authors:  M T Aguado; L H Perrin; P A Miescher; P H Lambert
Journal:  Arthritis Rheum       Date:  1981-10

10.  Solubilization of immune precipitates by six isolated alternative pathway proteins.

Authors:  T Fujita; Y Takata; N Tamura
Journal:  J Exp Med       Date:  1981-12-01       Impact factor: 14.307

View more
  15 in total

Review 1.  Complement deficiency.

Authors:  K M O'Neil
Journal:  Clin Rev Allergy Immunol       Date:  2000-10       Impact factor: 8.667

2.  Effect of complement on sizes of model immune complexes.

Authors:  L B Korolevskaya; K V Shmagel
Journal:  Dokl Biochem Biophys       Date:  2014-11-04       Impact factor: 0.788

3.  Immune adherence of nascent hepatitis B surface antigen-antibody complexes in vivo in humans.

Authors:  N Madi; J P Paccaud; G Steiger; J A Schifferli
Journal:  Clin Exp Immunol       Date:  1989-11       Impact factor: 4.330

4.  Familial properdin deficiency associated with chronic discoid lupus erythematosus.

Authors:  E R Holme; J Veitch; A Johnston; G Hauptmann; B Uring-Lambert; M Seywright; V Docherty; W N Morley; K Whaley
Journal:  Clin Exp Immunol       Date:  1989-04       Impact factor: 4.330

5.  Complement mediated inhibition of immune precipitation and solubilization generate different concentrations of complement anaphylatoxins (C4a, C3a, C5a).

Authors:  J A Schifferli; G Steiger; J P Paccaud
Journal:  Clin Exp Immunol       Date:  1986-05       Impact factor: 4.330

6.  Fast liver catabolism of C1q in patients with paraproteinaemia and depletion of the classical pathway of complement.

Authors:  J A Schifferli; M Pascual; G Steiger; M Schapira; J E Ryser; J Estreicher; A Dash
Journal:  Clin Exp Immunol       Date:  1987-07       Impact factor: 4.330

Review 7.  Complement activation and complement receptors in systemic lupus erythematosus.

Authors:  J P Atkinson
Journal:  Springer Semin Immunopathol       Date:  1986

8.  Substitution of a single amino acid (aspartic acid for histidine) converts the functional activity of human complement C4B to C4A.

Authors:  M C Carroll; D M Fathallah; L Bergamaschini; E M Alicot; D E Isenman
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

Review 9.  Complement deficiency and immune complex disease.

Authors:  K A Davies; J A Schifferli; M J Walport
Journal:  Springer Semin Immunopathol       Date:  1994

10.  Complement mediated inhibition of immune precipitation in rheumatoid arthritis: studies on interaction of heat aggregated IgG with IgM rheumatoid factor.

Authors:  M M O'Sullivan; N Amos; B D Williams
Journal:  Ann Rheum Dis       Date:  1988-08       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.